LifeMD (NASDAQ:LFMD) Rating Lowered to Sell at Wall Street Zen

LifeMD (NASDAQ:LFMD) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other research analysts also recently commented on the company. HC Wainwright dropped their price target on LifeMD from $13.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, November 19th. Lake Street Capital dropped their target price on shares of LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. KeyCorp reduced their price target on shares of LifeMD from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 19th. Mizuho decreased their price objective on shares of LifeMD from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of LifeMD in a research note on Wednesday, October 8th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $9.43.

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $3.85 on Friday. The business’s 50 day simple moving average is $5.88 and its 200 day simple moving average is $8.60. LifeMD has a 1 year low of $3.43 and a 1 year high of $15.84. The company has a market capitalization of $185.34 million, a P/E ratio of -22.65 and a beta of 1.57.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings data on Monday, November 17th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The business had revenue of $60.17 million during the quarter, compared to analysts’ expectations of $62.07 million. During the same period in the previous year, the company earned $0.09 earnings per share. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts anticipate that LifeMD will post -0.56 EPS for the current fiscal year.

Insider Activity

In related news, insider Nicholas P. Alvarez sold 75,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $5.92, for a total transaction of $444,000.00. Following the completion of the transaction, the insider directly owned 605,000 shares in the company, valued at $3,581,600. This represents a 11.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 18.40% of the company’s stock.

Institutional Trading of LifeMD

A number of hedge funds and other institutional investors have recently modified their holdings of LFMD. Nisa Investment Advisors LLC increased its holdings in shares of LifeMD by 148.5% during the second quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company’s stock worth $50,000 after buying an additional 2,185 shares in the last quarter. Tower Research Capital LLC TRC grew its position in LifeMD by 110.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after acquiring an additional 2,452 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in LifeMD by 1,004.9% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 5,171 shares of the company’s stock worth $70,000 after acquiring an additional 4,703 shares during the last quarter. Quarry LP acquired a new position in LifeMD in the 3rd quarter worth about $52,000. Finally, CWM LLC raised its position in LifeMD by 17.5% in the first quarter. CWM LLC now owns 9,050 shares of the company’s stock valued at $49,000 after purchasing an additional 1,351 shares during the last quarter. Institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.